

Amendments to the Claims

1. (Original) A method for lowering cholesterol absorption in a sustained manner by the use of a localized delivery of LXR and/or RXR agonists while also limiting, minimizing, or ameliorating the detrimental effect of LXR agonists on triglyceride levels via direct action in the liver.

2. (Original) A method for treating and/or preventing Cardiovascular Disease comprising impregnation of LXR agonists on a stent device.

3. (Original) A method for treating and/or preventing Cardiovascular Diseases comprising impregnation of RXR agonists on a stent device.

4. (Original) A method for treating and/or preventing Cardiovascular Diseases comprising impregnation of LXR and/or RXR agonists on a stent device.

5. (Original) A method according to Claim 1 or 3 wherein the LXR agonist is selected from a group consisting of: a compound of formula I, and a compound of formula II.

6. (Original) A composition comprising a therapeutically effective amount of a LXR agonist impregnated on a stent.

7. (Original) A composition comprising a therapeutically effective amount of a RXR agonist impregnated on a stent.

8. (Currently Amended) A composition according to ~~Claim 7 or 8~~Claim 6 or 7 wherein the LXR or RXR agonist is impregnated to effect a time-release (slow-release) formulation.

9. (Cancelled)

10. (Cancelled)